INmune Bio receives MHRA pediatric plan approval for Ebstrocel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026 7:00 AM EDTApproval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom in the United Kingdom
BOCA RATON, Fla, June 25, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the Company), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
The approval of the PIP is the first required stage toward a Marketing Authorization Application... More
